Piper Jaffray is maintaining its Overweight rating and its price target of $24 on Hologic Inc. HOLX, following a recent survey regarding 3D imaging and hurdles to adoption.
In the report, Piper Jaffray writes, “We recently conducted a survey of 500 community hospitals, private imaging centers and university hospitals designed to gage market demand for 3D imaging and assess potential hurdles for adoption. Specifically, 40% of current digital mammography users are considering an eventual transition to 3D tomosynthesis mammography, although only 5% have specific adoption plans. Not surprisingly, accounts cited lack of reimbursement (73%) and capital cost (63%) as the primary adoption hurdles. On average, accounts attributing reimbursement as a gaiting factor for adoption believe a 37% premium (median 30%) would be appropriate to justify an upgrade to 3D. We are encouraged with the survey results and believe incremental reimbursement levels for 3D above this 37% average would drive demand for 3D tomosynthesis upgrades/equipment purchases.”
HOLX closed yesterday at $21.45.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsHealth CareHealth Care EquipmentHologic Inc.Piper Jaffray & Co.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in